<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648462</url>
  </required_header>
  <id_info>
    <org_study_id>ProTRAIT-neuro</org_study_id>
    <nct_id>NCT04648462</nct_id>
  </id_info>
  <brief_title>Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology</brief_title>
  <official_title>Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HollandPTC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastro Clinic, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the&#xD;
      physical properties of protons, proton therapy has tremendous potential to reduce the&#xD;
      radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less&#xD;
      radiation-induced complications, and a decrease in the formation of secondary tumours. The&#xD;
      Netherlands has spearheaded the development of the model-based approach (MBA) for the&#xD;
      selection of patients for proton therapy when applied to prevent radiation-induced&#xD;
      complications. In MBA, a pre-treatment in-silico planning study is done, comparing proton and&#xD;
      photon treatment plans in each individual patient, to determine (1) whether there is a&#xD;
      significant difference in dose in the relevant organs at risk (ΔDose), and (2) whether this&#xD;
      dose difference translates into an expected clinical benefit in terms of NormalTissue&#xD;
      Complication Probabilities (ΔNTCP). To translate ΔDose into ΔNTCP, NTCP-models are used,&#xD;
      which are prediction models describing the relation between dose parameters and the&#xD;
      likelihood of radiation-induced complications. The Dutch Society for Radiotherapy and&#xD;
      Oncology (NVRO) setup the selection criteria for proton therapy in 2015, taking into account&#xD;
      toxicity and NTCP. However, NTCP-models can be affected by changes in the irradiation&#xD;
      technique. Therefore, it is paramount to continuously update and validate these NTCP-models&#xD;
      in subsequent patient cohorts treated with new techniques. In ProTRAIT, a Findable,&#xD;
      Accessible, Interoperable and Reusable (FAIR)data infrastructure for both clinical and 3D&#xD;
      image and 3D dose information has been developed and deployed for proton therapy in the&#xD;
      Netherlands. It allows for a prospective, standardized, multi-centric data from all Dutch&#xD;
      proton and a representative group of photon therapy patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Neurocognitive failure at 5 years</measure>
    <time_frame>5 years after radiotherapy</time_frame>
    <description>Time to neurocognitive failure, defined as the time from last radiotherapeutic treatment to the first instance of a measured HVLT-dr of -1.5Z based on the normal data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HVLT- delayed recall decline at 5 years</measure>
    <time_frame>5 years after radiotherapy</time_frame>
    <description>HVLT- delayed recall decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HVLT total recall decline at 5 years</measure>
    <time_frame>5 years after radiotherapy</time_frame>
    <description>HVLT total recall decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMT a decline at 5 years</measure>
    <time_frame>5 years after radiotherapy</time_frame>
    <description>TMT a decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMT b decline at 5 years</measure>
    <time_frame>5 years after radiotherapy</time_frame>
    <description>TMT b decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COWA total decline at 5 years</measure>
    <time_frame>5 years after radiotherapy</time_frame>
    <description>COWA total decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Astrocytoma</condition>
  <condition>Ependymoma</condition>
  <condition>Ganglioglioma</condition>
  <condition>Oligodendroglioma</condition>
  <condition>Optic Nerve Glioma</condition>
  <condition>Meningioma</condition>
  <condition>Nerve Sheath Neoplasms</condition>
  <condition>Adenoma</condition>
  <condition>Craniopharyngioma</condition>
  <condition>Hemangiopericytoma</condition>
  <condition>Germinoma</condition>
  <condition>Neurilemmoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ProTRAIT</intervention_name>
    <description>The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All neuro-oncological patients treated with proton therapy at one of the three proton&#xD;
        centers in the Netherlands&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All brain tumors with a favorable prognosis (median survival &gt; 10 year)&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. ECOG performance status 0 - 1 / Karnofsky performance status 80 - 100&#xD;
&#xD;
          4. No - minimal neurocognitive impairment&#xD;
&#xD;
          5. Dosimetrical gain of protontherapy relative to photontherapy (≥5% on supratentorial&#xD;
             brain dose or hippocampi)&#xD;
&#xD;
          6. Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not eligible for chemotherapy&#xD;
&#xD;
          2. Eligible for stereotactic radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Danielle Eekers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Eekers</last_name>
    <role>Study Chair</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiske van der Weide</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Kramer</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvonne Klaver</last_name>
    <role>Principal Investigator</role>
    <affiliation>HollandPTC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Kroesen</last_name>
    <role>Principal Investigator</role>
    <affiliation>HollandPTC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Mendez Romero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Jaspers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I Coremans</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaap Zindler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center Haaglanden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inge Compter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danielle Eekers</last_name>
    <phone>+31884455600</phone>
    <email>danielle.eekers@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiske van der Weide</last_name>
    <phone>+31503612711</phone>
    <email>h.l.van.der.weide@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Eekers</last_name>
      <phone>+31884455600</phone>
      <email>danielle.eekers@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Inge Compter</last_name>
      <phone>+31884455600</phone>
      <email>inge.compter@maastro.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Holland PTC</name>
      <address>
        <city>Delft</city>
        <state>Zuid-Holland</state>
        <zip>2629 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Klaver</last_name>
      <phone>+31885011100</phone>
      <email>y.klaver@hollandptc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jaap Zindler</last_name>
      <phone>+31885011100</phone>
      <email>j.zindler@hollandptc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 WS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiske van der Weide</last_name>
      <phone>+31503612711</phone>
      <email>h.l.van.der.weide@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Miranda Kramer</last_name>
      <phone>+31503612711</phone>
      <email>m.c.a.kramer@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Hemangiopericytoma</mesh_term>
    <mesh_term>Germinoma</mesh_term>
    <mesh_term>Ganglioglioma</mesh_term>
    <mesh_term>Optic Nerve Glioma</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurilemmoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

